Resources
BNET Resources
- sort by:
- Relevance
- Date
- Popularity
- Small Cap Stocks to Watch - DNDN, CECE, SWIM, OSTK, UNRG.
- M2 PRESSWIRE-15 January 2008-SmallCapReview.com: Small Cap Stocks to Watch - DNDN, CECE, SWIM, OSTK, UNRGC1994-2008 M2 COMMUNICATIONS LTD RDATE:15012008 Dendreon Corporation (Nasdaq: DNDN) Closed at $6.46. Today announced that the company has been granted a broad European patent covering the...
- Research articles 2008-01-15
- Dendreon Corp. SEC Launches Informal Probe.
- M2 PRESSWIRE-12 July 2007-investorIM: Dendreon Corp. SEC Launches Informal ProbeC1994-2007 M2 COMMUNICATIONS LTD RDATE:12072007 InvestorIM has been created as a tool for the average investor. The idea is simple, a website where the world can communicate. Do you have a stock...
- Research articles 2007-07-12
- Dendreon Corp. Added to Bellwether Watch List.
- M2 PRESSWIRE-11 July 2007-Biotech News: Dendreon Corp. Added to Bellwether Watch ListC1994-2007 M2 COMMUNICATIONS LTD RDATE:11072007 Dendreon wants to boost your immunity from the start. It is developing therapeutic vaccines that goose the body's immune system to help it fight cancer...
- Research articles 2007-07-11
- Dendreon To Present at American Urological Association Annual Meeting.
- M2 PRESSWIRE-21 May 2007-Headline Maker: Dendreon To Present at American Urological Association Annual MeetingC1994-2007 M2 COMMUNICATIONS LTD RDATE:21052007 Market Gainer is quickly emerging as the one stop shop for international small-cap investors looking to stay a step ahead of the ...
- Research articles 2007-05-21
- Speak with other shareholders about: (Pink Sheets: PEDG), (Nasdaq: DNDN), (OTCBB: USXP), (OTCBB: ZAAP).
- M2 PRESSWIRE-30 March 2007-Stockwire.com: Speak with other shareholders about: (Pink Sheets: PEDG), (Nasdaq: DNDN), (OTCBB: USXP), (OTCBB: ZAAP).C1994-2007 M2 COMMUNICATIONS LTD RDATE:30032007 AUSTIN, TX - A very interesting indicator to look for is where the money is flowing into. We have...
- Research articles 2007-03-30
- PEDG, DNDN, USXP, ZAAP - OTCStockExchange.com Stock Alert.
- M2 PRESSWIRE-30 March 2007-otcstockexchange.com: PEDG, DNDN, USXP, ZAAP - OTCStockExchange.com Stock AlertC1994-2007 M2 COMMUNICATIONS LTD RDATE:30032007 Rochester, NY - OTCStockExchange.com's "Stock Watch Alert" this morning are PrimEdge, Inc. (Pink Sheets: PEDG), Dendreon Corporation (Nasdaq: DNDN), Universal Express Inc. (OTCBB: ...
- Research articles 2007-03-30
- GNNO, DNDN, RCAU, USXP, GSCR "Red Hot Penny Stock Alert".
- M2 PRESSWIRE-30 March 2007-redhotpennystock.com: GNNO, DNDN, RCAU, USXP, GSCR "Red Hot Penny Stock Alert"C1994-2007 M2 COMMUNICATIONS LTD RDATE:30032007 Bull in Advantage, LLC a.k.a. Redhotpennystock.com names Great Northern Oilsands Inc.(Pink Sheets: GNNO), Dendreon Corporation (Nasdaq: DNDN), Rocket City Automotive Group (Pink...
- Research articles 2007-03-30
- NutraCea Announces Private Label Contract and CV Therapeutics Shares Rise on Coverage.
- M2 PRESSWIRE-22 January 2007-U.S. Equity News: NutraCea Announces Private Label Contract and CV Therapeutics Shares Rise on CoverageC1994-2007 M2 COMMUNICATIONS LTD RDATE:22012007 City of Industry, CA - Biotechnology industry alert provided by U.S. Equity News. NutraCea (OTC BB: NTRZ) recently announced...
- Research articles 2007-01-22
- Dendreon: Pro-Provenge Activists Heap Abuse on Cancer Drug’s Critics
- Dendreon: Pro-Provenge Activists Heap Abuse on Cancer Drug’s CriticsRE: Dendreon: Pro-Provenge Activists Heap Abuse on Cancer Drug’s CriticsThe final result has to show a 22% reduction in deaths. The interim showed a 20% reduction, closely matching previous trials. The final result of previous trials showed a 33% reduction...
- Discussion threads 2008-10-07
- Dendreon's Provenge Beats FDA Approval Standard By Just Half a Percent; Stock Plunges Before Rally
- Dendreon's IMPACT study of its cancer vaccine Provenge beat the FDA's 22 percent "reduction in risk of death" standard by just half a percent: The company said it reduced "risk of death" by 22.5 percent today. Dendreon stock plunged on the news and trading in it had to be halted,...
- Blog posts 2009-04-28
- Dendreon: Pro-Provenge Activists Heap Abuse on Cancer Drug’s Critics
- It's been a just a day since Dendreon announced that the interim analysis of its Provenge anti-prostate cancer candidate showed some -- but not enough -- improvement in sufferers, and already the drug's army of web activists is heaping abuse on those who suggest that possibly, just possibly, this drug...
- Blog posts 2008-10-07
Additional Resources
- Dendreon Investors Counting on FDA Approval of Provenge
- Zacks.com submits: Dendreon Corporation (DNDN - Analyst Report) is likely to become the first company to receive approval from the U.S. Food and Drug Administration (FDA) for an anti-cancer, immunotherapy based vaccine, as it released phase III IMPACT Immunotherapy for Prostrate AdenoCarcinoma Treatment trial results for its key...
- External links 2009-09-28
- Why Sales Estimates for Dendreon's Provenge Are Too Low
- Dan Rosenblum submits: After the initial excitement caused by the Phase 3 IMPACT study of Dendreon's DNDN Provenge for the treatment of metastatic prostate cancer has begun to fade along with the stock price, it is time to consider just how big a drug Provenge can become. ...
- External links 2009-05-18
- Dendreon 2007 Annual Report and How Provenge Will Propel Company
- Chris Katje submits: I have finally gotten around to writing about some of the annual reports I have sifted through in the past month. The first one I am writing about today is Dendreon DNDN, one of my Top Ten Stocks for 2009.Dendreon had a nice 2007 as far...
- External links 2009-01-27
- Dendreon's Provenge Looks Likely to Be Approved in Mid-2010
- VFC submits: Shares of Dendreon DNDN traded as much as five percent higher on Monday morning after the company announced that it has re-submitted its application for the regulatory approval of Provenge, a therapeutic prostate cancer vaccine that was called 'approvable' by the FDA in 2007. According to the...
- External links 2009-11-03
- Dendreon Still Faces Hurdles for Provenge Despite Positive Phase 3 Data
- Dendreon’s announcement that its Phase 3 prostate cancer vaccine Provenge “met its primary endpoint of improving overall survival” in the crucial IMPACT trial will likely have the prostate cancer activists dancing in the streets. But Provenge still faces significant scientific, regulatory and financial hurdles before it validates the massive expectations...
- Blog posts 2009-04-15
- Vultures Circle Dendreon Even Though Jury Is Still Out on Provenge
- Dendreon had better pull something amazing out of the hat when it gets the results of its "Impact" study on Provenge, the drug it's developing for prostate cancer -- because investors are already guessing that the results are not going to be good. Back in March, Dendreon...
- Blog posts 2008-08-15
- Dendreon Reports FDA Confirms Data Required for Provenge Licensure.
- M2 PRESSWIRE-31 May 2007-Making The Watchlist: Dendreon Reports FDA Confirms Data Required for Provenge LicensureC1994-2007 M2 COMMUNICATIONS LTD RDATE:31052007 Market Gainer is quickly emerging as the one stop shop for international small-cap investors looking to stay a step ahead of...
- Research articles 2007-05-31
- Dendreon Troubles Beyond Provenge Test
- Michael Steinberg submits: Dendreon DNDN is a company not unknown for hype. Today’s hype was that the Provenge prostate cancer immunotherapy met the Phase 3 survival goals of reducing death by 22% and extending life by 4.5 months for men with advanced prostate cancer who no longer responded to hormone...
- External links 2009-04-14
- Did News of Dendreon's Provenge Results Leak the Day Before the Announcement?
- Here's an open question on Dendreon's announcement Tuesday of positive results in its Provenge phase 3 studies: Did news of the results leak out among insiders on Monday, the day before the announcement? by Jim Edwards
- Blog posts 2009-04-16
- << Previous
- page 1 of 1
- Next >>
Premier Vendor Content Whitepapers, webcasts & resources from our Power Center Sponsors
